Lord’s Mark Industries, a diversified enterprise group, plans public itemizing within the first half of 2024 to boost Rs 500 crore.
The corporate will make investments the proceeds in its subsidiaries to develop medtech merchandise and diagnostic options, develop its pathology lab providers pan-India, and export medical diagnostic merchandise and machines.
Sachidanand Upadhyay, Managing Director, Lord’s Mark Industries mentioned the corporate’s main enterprise unit — diagnostic-medtech and solar-LED division — has been breaking new floor with a solution-oriented method.
Subsidiaries Lord’s Automative, Lord’s Mark Biotech, Lord’s Mark Microbiotech, and Lord’s Mark Insurance coverage Broking Companies plan to deepen market penetration, and the itemizing will gas additional development, he mentioned.
The corporate reported income from operations at Rs 301 crore (Rs 213 crore) in FY23, registering a 41 per cent development.
Included in 1998, Lord’s Mark Industries transitioned from paper business to Photo voltaic-LED, medical-diagnostic, and hygiene segments. It has an R&D facility and workforce for medical diagnostic and medtech merchandise.
The corporate, via its subsidiary, has launched saliva-based genome testing via its model MyDNA. It has collaborated with Dozee, IIT Bombay, BARC to revamp medical infrastructure
IDBI Capital and Mirae Asset are the service provider bankers for the itemizing.
